All product descriptions and articles provided on this website are intended strictly for informational and educational purposes. Our products are designed exclusively for in-vitro research (i.e., experiments conducted outside of a living organism, typically in glassware such as test tubes or petri dishes). These compounds are not approved by the FDA for use in humans or animals. They are not medications, nor are they intended to diagnose, treat, prevent, or cure any disease or medical condition. Any bodily administration-human or animal-is strictly prohibited by law. Our products are not for human consumption under any circumstances.
Short answer: six human studies of AOD-9604 were run between 2001 and 2006, but only two measured weight loss over months — and they disagree. The 12-week trial in 300 obese adults found the best-performing dose beat placebo by roughly 2 kg, a modest edge and the largest signal the program ever produced. The follow-up 24-week Phase 2b, in about 500 obese subjects at 0.25 to 1 mg daily, showed no meaningful weight-loss separation from placebo at any dose, and the sponsor, Metabolic Pharmaceuticals, ended the obesity program in February 2007.
That second trial is the one almost nobody quotes. Its efficacy data was never published in a peer-reviewed journal; only the safety and tolerability arm was, in 2013, reporting a profile indistinguishable from placebo. Pages that still call AOD-9604 “highly successful in trials” are recycling a December 2004 press release written three years before the program was stopped.
Two details get lost in the summaries. AOD-9604 clears fast: a plasma half-life of about three to four minutes after intravenous dosing, with slower absorption orally, which is how both weight-loss trials administered it. And the GRAS classification it later received as a food ingredient is a food-safety category, not FDA approval as a drug — the two are constantly conflated. Material sold under this name, including AOD-9604 5mg, is supplied for research use only.
How AOD-9604 Works: Fat Metabolism Explained
AOD 9604 affects fat metabolism by targeting specific biochemical pathways that regulate how the body stores and breaks down fat. It acts selectively on lipid metabolism, avoiding the broader hormonal effects seen with full growth hormone treatments.
Recent findings highlight its key actions:
- Stimulates lipolysis by activating enzymes that facilitate the release of stored fat.
- Suppresses lipogenesis by reducing acetyl-CoA carboxylase activity in cells.
- Enhances fatty acid oxidation by regulating beta-3 adrenergic receptor expression.
Moreover, AOD 9604 demonstrates strong metabolic activity by enhancing fat breakdown and regulating weight gain in preclinical studies. The research published on Karger[1] showed that obese Zucker rats treated orally with AOD 9604 had over 50% less body weight gain and increased lipolytic activity. Importantly, no adverse effects on insulin sensitivity were observed, confirming its safe metabolic profile in controlled studies.
AOD-9604 Half-Life and Side Effects Reported in Trials
AOD 9604 demonstrates a favorable safety and pharmacokinetic profile across multiple toxicology and clinical studies. Research consistently shows low toxicity, minimal immunogenicity, and no significant adverse effects in controlled experimental conditions, supporting its suitability for scientific investigation rather than therapeutic application.
Extensive evidence highlights its key safety characteristics:
- No genotoxic or mutagenic activity: The JofEM study[2] on AOD 9604 reported no genotoxic effects in rats and cynomolgus monkeys during Ames, chromosomal aberration, and bone micronucleus assays. These findings confirm its strong genetic safety profile under controlled laboratory conditions.
- Minimal immunogenic potential: Long-term studies in rodents and primates report no antibody formation, suggesting a low risk of immune reactions following repeated exposure to the peptide.
- No organ or biochemical toxicity: Extended oral dosing trials indicate stable organ function, hematology, and biochemistry parameters, emphasizing the peptide’s consistent safety across multiple study models.
Moreover, pharmacokinetic evaluations reveal that AOD 9604 has a short plasma half-life of about three to four minutes intravenously and slower absorption when administered orally. Consequently, its rapid metabolism into active fragments and lack of systemic accumulation highlight a strong clearance profile, reducing the potential for peptide build-up or toxicity.
AOD-9604 Results: What the Human Trials Showed
Clinical trials reveal that AOD 9604 shows strong efficacy in supporting fat metabolism and metabolic regulation. A Journal of Endocrinology and Metabolism[3] study reported consistent reductions in body fat, improved glucose tolerance, and stable IGF-1 levels. Moreover, participants exhibited excellent tolerability and no severe adverse events. These findings confirm AOD 9604’s safety and effectiveness in controlled metabolic research environments.
However, subsequent trials incorporating dietary and exercise interventions produced less conclusive results. Even so, the moderate fat loss observed aligns with AOD 9604’s targeted mechanism rather than broad hormonal activity. Additionally, the absence of IGF-1 stimulation distinguishes it from growth hormone therapies. Overall, clinical evidence supports its potential as a controlled research peptide for metabolic health studies, not as a therapeutic agent.
AOD-9604 Results in Animal Studies
Preclinical and animal studies validate the clinical findings on AOD 9604 by demonstrating its clear impact on fat metabolism and β3-adrenergic receptor activity. According to a Monash University[4] study, AOD 9604 enhanced lipolysis, increased β3-AR expression, and reduced body fat in obese mice, supporting its translational metabolic relevance.
Robust evidence highlights three major research insights:
1. Enhanced Fat Metabolism
Animal studies in rodents and pigs show increased lipolysis and reduced fat accumulation during chronic dosing. These results parallel human data, confirming consistent metabolic benefits through improved fat breakdown and regulated lipid storage.
2. Elevated Energy Expenditure
Preclinical findings demonstrate higher energy expenditure and greater fat oxidation in obese models. This aligns with observed metabolic improvements in clinical trials, reinforcing the peptide’s role in supporting balanced energy utilization and metabolic efficiency.
3. Strong Safety and Target Specificity
Toxicology and distribution studies reveal safety even at high doses. Radiolabeled trials indicate targeted peptide accumulation in the pancreas, liver, and adipose tissue, suggesting precise metabolic activity without systemic toxicity.
Purity and Stability Issues That Affect AOD-9604 Studies
Researchers in metabolic regulation often encounter difficulties accessing high-purity compounds and maintaining peptide stability during experiments. These inconsistencies can lead to data variability and hinder reproducibility. As a result, drawing precise conclusions about complex processes, such as fat oxidation, lipid metabolism, and overall energy balance, becomes a significant challenge in controlled research settings.
At Prime Lab Peptides, we offer research-grade AOD 9604 built for reproducibility and scientific precision. Our commitment lies in quality control, transparency, and reliable sourcing. This helps researchers overcome common experimental challenges with confidence. For more details or to explore collaboration opportunities, please contact us to support your next research study.
Compounds referenced above, in the Prime Lab Peptides catalog:
- AOD-9604 – 5mg — the fragment discussed throughout this article; purity documentation and third-party test results sit on the product page.
- Tesamorelin – 10mg — a growth-hormone-releasing analogue with a different mechanism, sometimes used as a comparator in adipose-tissue study designs.
- GLP-1SG – 10mg — a GLP-1 receptor-targeting compound used in separate metabolic research lines.
Why AOD-9604 Leaves IGF-1 Flat: The Receptor Evidence
IGF-1 stays flat because the fragment cannot switch on the growth hormone receptor in the first place. That mechanism sits underneath the "no IGF-1 rise" line, and it comes from binding assays rather than from the weight-loss trials.
In the International Journal of Obesity study from the Monash group, cells transfected with the hGH receptor were exposed to AOD9604 alongside radiolabelled hGH. The fragment did not compete for the receptor, and it did not induce cell proliferation. Intact hGH did both in the same assay. That single comparison is the strongest direct evidence that the two molecules do not share a signalling route, even though one is a piece of the other.
The structure explains why. AOD-9604 is Tyr-hGH177-191: a short sequence copied from the C-terminus of human growth hormone, with a tyrosine added at the front. hGH activates its receptor by bridging two receptor molecules through two separate contact surfaces. Binding site 2 is entirely absent from the fragment, so the dimerisation step that starts the signal cannot happen — and without that signal there is no downstream IGF-1 response. Material sold as "hGH fragment 176-191" is the same sequence counted under a different residue-numbering convention, not a different compound.
The human record is consistent with the assay. Across the six placebo-controlled trials run between 2001 and 2006, serum IGF-1 in treated subjects did not separate from placebo, as reported in the 2013 safety and tolerability paper.
Worth stating plainly: this is receptor binding in vitro plus a circulating hormone measured in blood. Neither is a direct measurement of what happens in muscle or any other anabolic tissue.
Does AOD-9604 Spare Lean Muscle? What the Studies Actually Measured
No published AOD-9604 study measured lean mass. The "fat loss without muscle loss" framing that circulates online is an inference drawn from the receptor data, not a result reported by any trial — and the distinction matters if you are designing a study or comparing compounds.
Here is what the published record does contain:
- Animal work: body weight gain, adipose tissue lipolytic and lipogenic activity, fat and glucose oxidation, energy expenditure, and adipocyte size. The Journal of Molecular Endocrinology study of the untagged 177-191 fragment reported average adipocyte diameter falling from roughly 110 to 80 micrometres in treated obese Zucker rats after a 20-day course. That is an adipose measurement, not a body composition measurement.
- Human trials: body weight, serum IGF-1, glucose and insulin, vital signs, ECGs, laboratory panels and anti-peptide antibodies. The published safety paper reports none of these as a body composition breakdown, and the efficacy dataset from the 24-week Phase 2b was never published at all.
So the honest position is that muscle was never an endpoint. The mechanistic expectation is reasonable — a fragment that does not engage the hGH receptor should not drive anabolic signalling in either direction — but expectation and measurement are different things, and only one of them belongs in a methods section.
This also makes any head-to-head against GLP-1 receptor agonists asymmetric. Those programs have published body composition endpoints that can be argued over. AOD-9604 has none, so the comparison rests on mechanism alone.
Does AOD-9604 Act on Appetite?
The animal data point away from appetite. In the American Journal of Physiology: Endocrinology and Metabolism study, obese ob/ob mice given the fragment orally for 30 days gained significantly less weight than saline controls from day 16 onward — while food consumption did not differ between the two groups. Whatever produced the divergence, it was not the animals eating less.
Two qualifications belong with that finding. First, the compound in that experiment was AOD-9401: the same hGH 177-191 sequence, without the N-terminal tyrosine that defines AOD-9604. Second, it is a rodent result, and the published human trials never reported appetite or food-intake endpoints at all, so there is no human counterpart to cite.
The same paper adds a detail rarely quoted: alongside the rodent work, the fragment increased lipolytic activity and decreased lipogenic activity in isolated adipose tissue taken from humans, not only from obese rodents. That is an ex vivo tissue observation rather than a clinical outcome, but it is one of the few places where the proposed mechanism was tested on human tissue directly.
For anyone framing an experiment, this is the useful separation. Appetite-mediated compounds and adipose-mediated compounds produce weight change through different routes, and they demand different endpoints — food intake logs on one side, lipolytic markers and substrate oxidation on the other. The AOD-9604 literature was built almost entirely on the second set.
FAQs
What makes AOD 9604 valuable in metabolic research?
AOD 9604 is valuable because it specifically targets lipid metabolism pathways without broad hormonal interference. It helps researchers analyze fat oxidation and energy regulation mechanisms. Moreover, its selective action provides controlled insights for experimental metabolic studies.
How does AOD 9604 differ from full hGH?
AOD 9604 differs by acting on fat metabolism without elevating IGF-1 levels. This selectivity reduces systemic effects seen with full growth hormone. Consequently, it allows researchers to study isolated metabolic responses more accurately.
What do pharmacokinetic studies reveal about AOD 9604?
Pharmacokinetic studies show that AOD 9604 has a short plasma half-life with rapid metabolism into active fragments. These fragments remain bioactive, maintaining metabolic influence. Thus, it demonstrates efficient clearance and limited systemic accumulation.
How do preclinical studies support AOD 9604 findings?
Preclinical studies confirm increased lipolysis, improved fat oxidation, and enhanced energy expenditure in animal models. These outcomes align with the results of human trials. Therefore, they provide a strong translational foundation for metabolic research applications.
References
1 comment
https://healthlabpeptides.com/product/bpc-157/